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In the large majority of patients, ventricular arrhythmias are
caused by myocardial ischaemia and/or infarction because of
underlying coronary artery disease. Also, nonischaemic car-
diomyopathy, infiltrative disease (e.g. sarcoidosis, amyloid-
osis) and infectious disease (e.g. viral myocarditis) are reason-
ably frequent causes of ventricular arrhythmias. Obviously, in
these cases, treating the underlying disease is the primary goal.
However, ventricular arrhythmias also occur in patients with
primary inherited arrhythmia syndromes such as catechol-
aminergic polymorphic ventricular tachycardia (CPVT) and
long-QT syndrome (LQTS). CPVT and LQTS are rare causes
of ventricular arrhythmias, and predominantly occur in young
patients, with apparently structurally normal hearts. The ven-
tricular arrhythmias occur mainly under conditions of in-
creased sympathetic activity (e.g. physical or emotional stress)
[1]. In these patients, besides removal of triggers, the corner-
stone of treatment of these diseases isβ-adrenoreceptor block-
ade. Treatment with beta-blockers is currently a class I indi-
cation in clinically diagnosed patients suffering from ventric-
ular arrhythmias [2]. Beta-blockade should be titrated up to an
effective level. If not sufficient, adding flecainide in the case
of CPVT appears to be a sensible approach [3]. Implantation
of an internal cardioverter defibrillator (ICD) can be consid-
ered in the (rare) patient not adequately controlled with med-
ical interventions. However, the use of an ICD alone is also
not the panacea because of the catecholamine release, trig-
gered by the pain and fear generated by ICD shocks, which
may subsequently initiate arrhythmic storms and/or multiple
shocks and may even lead to death [4]. Therefore, continua-
tion of medical therapy in the maximal tolerable dose is
mandatory, also after ICD implantation.
Left cardiac sympathetic denervation (LCSD) may be con-
sidered for patients with CPVT and LQTS who suffer from
recurrent ventricular tachycardias despite maximal pharmaco-
logical therapy [5]. Historically, sympathectomy has been
used as a treatment modality for angina pectoris [6].
From the 1970s cardiac sympathetic denervation has
been described for the treatment of (treatment-resistant)
ventricular arrhythmias [7].
In the current issue of the Netherlands Heart Journal,
Olde Nordkamp and co-workers present their experi-
ence of LCSD in treating therapy-resistant patients with
inherited arrhythmia syndromes. [8] They are a tertiary
referral centre for this patient cohort in the Netherlands,
being the only centre in this country performing this
surgical procedure. The baseline characteristics of the
described patients show the disease state, since all
patents were on beta-blockade and the majority of pa-
tients suffering from CPVT were also taking flecainide.
Despite maximal medical therapy these patients were
still experiencing adverse events (arrhythmias, syncope).
The majority of patients underwent a video-assisted
thoracoscopic approach, some using the supraclavicular
approach and one patient underwent LCSD via
thoracotomy.
The clinical results presented are reassuring; in gen-
eral, a nice 87 % of symptomatic patients experienced a
decreased cardiac event rate after LCSD. However, only
47 % of the patients did not experience any cardiac
events, while 53 % of the patients remained symptom-
atic (although to a lesser extent) during a median
follow-up of 34 (IQR 16–77) months. These numbers
are comparable with previous reports from other
(foreign) centres [9].
This reduction of ventricular arrhythmias after LCSD,
however, comes at a cost; the risk for serious peri-procedural
complications was 12 % (2 out of 17 patients) in the
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current patient cohort. One patient had a permanent
postoperative Harlequin face and one (severely affected)
LQT (type 8) patient died postoperatively because of
multi-organ failure after several problems following
multiple arrhythmic storms. Furthermore, three patients
suffered from a post-procedural pneumothorax and one
patient experienced a transient Horner’s syndrome. It is,
however, to be expected that more experience with this
treatment modality will result in a reduction of the
(serious) adverse events in the future.
Therefore, the conclusion of this retrospective analysis
investigating the safety and efficacy of LCSD of patients with
LQTS and CPVT, not responding well to pharmacological
therapy, must be that it offers a valuable addition to the
medical therapy for patients with CPVT and LQTS, suffering
from repetitive ICD shocks and/or ventricular arrhythmias.
However, the other side of the coin must be taken into account
in all cases, since it is not a minor intervention without risks. If
risks and benefits are discussed and understood properly by
the (in general young) patient it offers a potential escape for
the often-traumatic events of otherwise untreatable ventricular
arrhythmias and ICD shocks.
New, less invasive techniques to decrease sympathetic activ-
ity, such as for example a percutaneous modality, which makes
use of a steerable radiofrequency catheter by creating lesions to
perivascular aligned nerve branches of the renal arteries, might
be another option to decrease the adrenergic stress on the heart,
thereby decreasing the arrhythmia burden in these patients [10].
The possibilities and potential benefits in the case of this specific
indication are, however, purely speculative.
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